Xencor (XNCR) Income from Non-Controlling Interests (2023 - 2025)
Xencor's (XNCR) quarterly Income from Non-Controlling Interests came in at -$97000.0 in Q2 2025, up 80.52% year-on-year from -$53733.0 in Q2 2024, and down 109.53% on a QoQ basis from $1.0 million in Q1 2025.
Xencor (XNCR) Income from Non-Controlling Interests (2023 - 2025) Analysis & Trends
Xencor (XNCR) has 3 years of Income from Non-Controlling Interests data on file, last reported at -$97000.0 in Q2 2025.
- On a quarterly basis, Income from Non-Controlling Interests rose 80.52% year-over-year to -$97000.0 in Q2 2025; TTM through Mar 2026 was -$97000.0, a 114.12% decrease from a year earlier, with the FY2025 full-year figure at -$214000.0, up 89.05% from the prior year.
- Income from Non-Controlling Interests for Q2 2025 stood at -$97000.0, down from $1.0 million in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for XNCR reached as high as $1.3 million in Q4 2024 and fell as low as -$1.4 million in Q1 2024.
- Historically, Income from Non-Controlling Interests has averaged -$145428.6 across 3 years, with a median of -$163000.0 in 2023.
- Across the five-year window, Income from Non-Controlling Interests soared 910.43% in 2024 and jumped 80.52% in 2025, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at -$163000.0 in 2023, then surged by 910.43% to $1.3 million in 2024, then slumped by 107.34% to -$97000.0 in 2025.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$97000.0 in Q2 2025, $1.0 million in Q1 2025, and $1.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Xencor | 1.49 Bn | 1.11 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -97,000.00 |
| Mar 31, 2025 | 1.02 Mn |
| Dec 31, 2024 | 1.32 Mn |
| Sep 30, 2024 | -1.15 Mn |
| Jun 30, 2024 | -498,000.00 |
| Mar 31, 2024 | -1.45 Mn |
| Dec 31, 2023 | -163,000.00 |